The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.
A new non-opioid painkiller, JournaVX, has received approval from the FDA, marking the first new type of pain medication in ...
Almost 1,200 people in Kern County have died from fentanyl overdoses since 2018, including 171 in 2024 and an all-time high of 294 the year before, according to updated numbers from the Kern ...
An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...
The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.
It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and overdose associated with opioids.
The FDA has approved suzetrigine, a new, non-opioid medication for adults with moderate to severe acute pain.
Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid medication for treating moderate to severe acute pain in adults. Journavx, approved ...